We are delighted to announce the appointment of Dr Nicole Mather as Chair of our new Science Advisory Group. As Chair, she will play a central role in shaping the scientific strategy for our growing C...

@drsamuelbhume, not on #Bluesky, on Another approval for anti-PD1 immunotherapy: Cemiplimab just got FDA-approved to reduce recurrence of high-risk squamous cell skin cancer (after surgery and radiot...

Patients who have cutaneous squamous-cell carcinoma with high-risk features are at risk for recurrence after definitive local therapy. The benefit of systemic adjuvant therapy options has not been ...

A new version of nanorate DNA sequencing, with an error rate lower than five errors per billion base pairs and compatible with whole-exome and targeted capture, enables epidemiological-scale studies of somatic mutation and selection and the generation of high-resolution selection maps across coding and non-coding sites for many genes.

@ewanbirney.bsky.social on the new version of Alphafold at the @emblebi.bsky.social www.ebi.ac.uk AlphaFold has been a transformation not just in structural biology but also - due to its ability to b...

Deeper collaboration between EMBL-EBI and Google DeepMind brings updates to the AlphaFold Database.

@nobelprize.bsky.social Our immune system is an evolutionary masterpiece. Every day it protects us from the thousands of different viruses, bacteria and other microbes that attempt to invade our bodi...